Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity

In the United States, the lifetime risk of a cancer diagnosis is nearly 40%; in 2016, that represents almost 1.6 million new patients, and despite advances in early diagnosis and treatment, roughly 35% will ultimately die of their malignancy. Fortunately, the number of patients living with a cancer diagnosis also continues to expand, anticipated to be more than 19 million in less than a decade. In calculating the relative risks and benefits of therapy, it is therefore important to consider the morbidity and mortality associated with antitumor therapy itself.

Source: Cardiovascular Pathology - June 30, 2017 Category: Cardiology Authors: Carolyn Kwak Glass, Richard N. Mitchell Tags: Review Article Source Type: research